Temple University Gastroparesis Clinical Center

天普大学胃轻瘫临床中心

• 批准号: 9357609
• 负责人: HENRY PAUL PARKMAN
• 金额: $ 36.15万
• 依托单位: TEMPLE UNIV OF THE COMMONWEALTH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-15 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9357609
• 关键词: Abdominal Pain; Agonist; Applications Grants; Area; Biological Markers; Biopsy; Biopsy Specimen; Buspirone; Chronic; Clinical; Clinical Data; Clinical Research; Comorbidity; Diagnosis; Disease; Etiology; Evaluation; Fibrosis; Freezing; Functional disorder; Gastric Emptying; Gastroparesis; Genetic Transcription; Goals; Grant; Histologic; Impairment; Investigation; Location; Maintenance; Malnutrition; Measures; Minority; Multicenter Studies; National Institute of Diabetes and Digestive and Kidney Diseases; Natural History; Nausea and Vomiting; Outcome; Pathogenesis; Pathologic; Pathology; Patient-Focused Outcomes; Patients; Periodicity; Physicians; Physiological; Predictive Factor; Prevalence; Pyloric antrum; Quality of life; Questionnaires; Recruitment Activity; Registries; Research; Sampling; Serotonin; Severities; Site; Specimen; Stomach; Symptoms; Techniques; Testing; Thick; Tissue Sample; Tissues; United States National Institutes of Health; Universities; Visit; cellular pathology; chronic pancreatitis; diabetic; early satiety; effective therapy; follow-up; gastrointestinal symptom; improved; improved outcome; insight; interest; motility disorder; multidisciplinary; novel; patient population; programs; receptor; repository; response; symptom treatment; targeted treatment; transcriptome sequencing; transcriptomics; treatment response; treatment strategy

PROJECT SUMMARY Patients with gastroparesis often suffer with chronic gastrointestinal symptoms that are not adequately treated due to both a lack of understanding of the underlying pathophysiology and lack of effective treatments. The participation of Temple University as a clinical center in the NIDDK Gastroparesis Clinical Research Consortium and the proposed studies will help achieve the broad, long term objectives of improving the understanding and treatment of patients with gastroparesis. The PI and Temple University are well qualified to continue to be one of the clinical centers in this consortium. Temple University has clinical expertise and an active research program in the evaluation and treatment of patients with gastroparesis. The aims for this renewal of the Gastroparesis Consortium are threefold. First, to better understand the pathologic basis of gastroparesis by continuing to provide gastric full thickness biopsy specimens from patients with gastroparesis. We are now collecting specimens from the antrum and obtaining freshly frozen tissue for RNA expression. Second, to better understand the clinical manifestations and pathophysiology of patients with symptoms of gastroparesis by maintaining and expanding the Gastroparesis Registry. Our goal is to have four years of follow-up on patients which will require maintenance of the Registry and continued periodic follow-up visits. We propose to continue recruitment of new patients. Refinements to existing questionnaires and pathophysiologic measures, as well as new ones, will allow us to answer questions related to the pathogenesis, severity grading, complications, treatment responses, and clinical outcomes in patients with gastroparesis. Third, to conduct new multicenter studies of gastroparesis investigating the pathophysiology, diagnosis, and treatment. Our application proposes three studies, each aimed at the understanding of the pathophysiology of symptoms and treatment of symptoms from gastroparesis. Improved testing will better associate pathophysiology with gastroparesis symptoms and ultimately enable targeted therapy to the underlying gastric pathophysiologic abnormality. Our first study will determine the effect of the 5HT-1 receptor agonist, buspirone, on early satiety and intragastric meal distribution in patients with symptoms of gastroparesis. Our second study is an evaluation of abdominal pain in gastroparesis, determining the prevalence of and response to treatment for chronic pancreatitis. Finally, our third study will assess the clinical outcome of patients undergoing endoscopic pyloromyotomy for gastroparesis, looking at the response and predictive factors for clinical improvement with this novel treatment. These three studies will ultimately enable physicians to better target therapy to the underlying pathophysiologic abnormalities in patients with gastroparesis. Temple's participation in the NIH Gastroparesis Clinical Consortium and the undertaking of Temple's proposed studies will help achieve the goal of the consortium by advancing our understanding of the pathophysiology and developing appropriate treatments for patients with symptomatic gastroparesis.

项目摘要 胃轻瘫的患者通常患有慢性胃肠道症状，未得到充分治疗 由于缺乏对潜在的病理生理学和缺乏有效治疗的理解。这 Temple University作为NIDDK胃轻瘫临床研究的临床中心的参与 财团和拟议的研究将有助于实现改进的广泛，长期的目标 了解和治疗胃轻瘫患者。 PI和Temple University有资格 继续成为该财团的临床中心之一。坦普大学有临床专业知识和 主动研究计划在评估和治疗胃轻瘫患者中。目的 胃清洗联盟的更新三倍。首先，更好地了解 通过继续提供胃轻瘫患者的胃全厚性活检标本来胃轻瘫。 现在，我们正在从鼻trum中收集标本，并获得新鲜冷冻的组织以进行RNA表达。 第二，以更好地了解患有症状的患者的临床表现和病理生理学 通过维持和扩大胃肉食注册中心，胃轻瘫。我们的目标是要有四年 对需要维护注册表和继续定期随访的患者进行后续行动。 我们建议继续招募新患者。对现有调查表的改进，并 病理生理措施以及新措施将使我们能够回答与 发病机理，严重程度分级，并发症，治疗反应和临床结果 胃轻瘫。第三，为研究病理生理学的胃肉食进行新的多中心研究， 诊断和治疗。我们的申请提出了三项研究，每个研究旨在理解 症状的病理生理和胃轻瘫症状的治疗。改进的测试会更好 将病理生理学与胃肉食症状相关联，并最终使有针对性的治疗 潜在的胃病理生理异常。我们的第一个研究将确定5HT-1受体的效果 激动剂，丁螺酮，关于症状的患者的早期饱腹感和胃内饮食分布 胃轻瘫。我们的第二项研究是评估胃轻瘫的腹痛，确定 慢性胰腺炎治疗的患病率和反应。最后，我们的第三项研究将评估临床 接受内窥镜幽门肌切除术进行胃轻瘫的患者的结局，研究反应和 通过这种新型治疗方法可以改善临床的预测因素。这三项研究最终将启用 医生可以更好地靶向治疗对患者的潜在病理生理异常 胃轻瘫。 Temple参与NIH胃轻瘫临床财团和承诺 坦普尔的拟议研究将通过促进我们对美国的理解来帮助实现财团的目标 病理生理学并为有症状性胃轻瘫的患者开发适当的治疗方法。